| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.42 | 1e-15 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.4 | 5e-15 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.29 | 1e-07 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.2 | 0.0003 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.18 | 0.0008 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.12 | 0.07 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.084 | 0.08 |